Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04961515 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma

StatusRecruiting
PhasePhase 2
Started2021-07-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 31, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
This phase II trial is evaluating the efficacy and side effect of orelabrutinib, sintilimab and temozolomide as possible treatments for relapsed or refractory central nervous system lymphoma.

Amendment history 1 change detected by DataLookout

2026-08-09
notable
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
WasSecond Affiliated Hospital, School of Medicine, Zhejiang University
NowSecond Affiliated Hospital, Zhejiang University, School of Medicine
Trial Details
NCT Number NCT04961515
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Sir Run Run Shaw Hospital, First Affiliated Hospital of Zhejiang University, Wenzhou Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Zhejiang Provincial Tongde Hospital, First People's Hospital of Hangzhou, Zhejiang Provincial People's Hospital, Jinhua Central Hospital, Jinhua People's Hospital, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Huzhou Central Hospital
Conditions Primary Central Nervous System Hodgkin Lymphoma
Enrollment 19 participants
Start Date 2021-07-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-31